During this process, oxidized LDL (OxLDL), generated by modification of LDL with oxidative stress, is taken up by macrophages 4) . Thus, inhibition of OxLDL-induced macrophage foam-cell formation may contribute to the prevention of atherosclerosis 5) . ACEIs have been shown to attenuate the development of atherosclerosis in hypercholesterolemic animal models. For example, ramipril reduced OxLDL uptake of macrophages in ApoE knockout mice 6) , and treatment with ACEIs inhibited LDL oxidation 7, 8) . These atheroprotective activities of ACEIs potentially contribute to their beneficial effects, which have been shown in several clinical trials.
Introduction
It is evident that dyslipidemia and the renin angiotensin system play a crucial role in atherogenesis 1) . Angiotensin-converting enzyme inhibitors (ACEIs) exert beneficial effects on vascular function and protect against atherosclerosis and cardiovascular events 2, 3) . One of the initial events during atherosclerosis development is the appearance of lipid-loaded foam cells derived from macrophages in the arterial intima. metabolism, which modurates such inflammatory processes as cell adhesion 12) . Moreover, they are able to bind directly to matrix metalloproteinase (MMP)-9 and suppress its activity 13, 14) , leading to cardiovascular protection 15, 16) . MMPs are endopeptidases capable of cleaving components of the extracellular matrix, and their expressions have been documented in a variety of cell types, including smooth muscle cells, endothelial cells, and macrophages. Furthermore, several members of the MMP family are found in atherosclerotic plaques 17, 18) and arterial aneurysms 19) . MMP-9, also known as gelatinase B, processes multiple extracellular substrates, including denatured collagen , fibronectin, and laminin. OxLDL upregulates MMP-9 expression in THP-1 macrophages by activating the MEK/ERK signaling pathway 20, 21) , while a recent report noted that deletion of MMP-9 reduced the growth of atherosclerotic lesions in ApoE knockout mice 22) . MMP-9 inhibition decreases macrophage migration, plaque rupture, smooth muscle cell proliferation and angiogenesis, but the causative role of MMP-9 in OxLDL-induced macrophage foam-cell formation is unknown.
In the present study, we investigated the potential role of imidaprilat, an active metabolite of imidapril, in macrophage foam-cell formation, as well as the possible association of MMP-9 in that process.
Material and Methods

Reagents and Antibodies
Imidaprilat was kindly provided by Mitsubishi Tanabe Pharma Corporation, Osaka, Japan. The reagents used in the present study were phorbol 12-myristate 13-acetate (PMA), Cholesterol kit (Denka Seiken), Triglyceride E test reagent (Wako), RPMI 1640 and Dulbecco's phosphate-buffered saline (DPBS) (Sigma). The antibodies were anti-p p38 mitogen-activated protein kinase (MAPK) and antip38 MAPK (Cell Signaling), anti-MMP-9 (Chemicon International), anti-CD36, anti-pERK, anti-ERK1, anti-tubulin (Santa Cruz), and anti-LOX-1 and anti-scavenger receptor A (SR-A) (R&D Systems). We also utilized an MMP-2/9 inhibitor (Calbiochem).
Cell Culture
THP-1 cells, a human monocytic cell line, were obtained from the American Type Culture Collection (ATCC) and European Collection of Cell Cultures (ECACC). THP-1 cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 100 IU/mL penicillin, 100 g/mL streptomycin, and 2 mmol/L L-glutamine in a humidified atmosphere of 5% CO2 at 37 . To examine cell viability, THP-1 cells were stained with DAPI solution after incubation with imidaprilat, the MMP-2/9 inhibitor, or OxLDL.
Preparation of LDL
Human LDL (1.019 to 1.063 g/mL) was isolated from the plasma of healthy human subjects by sequential ultracentrifugation at 4 , and then oxidized by exposure to CuSO4 (10 mol/L) in DPBS at 37 for 24 hours. OxLDL was extensively dialyzed against 0.24 mmol/L EDTA-saline. The level of endotoxin was measured using an E-Toxate kit (Wako) and found to be consistently less than 0.03 EU/mL (lowest detection limit).
Immunoblotting
Lysates were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then Western blotting was carried out with the antibodies as described above.
Oil Red O Staining
THP-1 macrophages were seeded into multi-well slides (Nunc) at a concentration of 2 10 5 cells per well. The cells were washed 3 times with DPBS, fixed with formaldehyde, and stained with oil red O. Lipid accumulation was observed under a microscope.
Cellular Lipid Analysis
To determine intracellular lipid contents, THP-1 macrophages were washed with DPBS and then removed from the culture plates, after which intracellular lipids were extracted using isopropanol. Triglyceride (TG) and total cholesterol (TC) were measured using an enzymatic method.
MMP Activity Measurement
MMP activity in THP-1 macrophages was measured using two different methods.
a) Gelatin Zymography
Gelatin zymography of THP-1 macrophages was conditioned as previously described 17) . Cells were seeded at 2 10 6 cells/mL in medium containing PMA at 200 nmol/L for 3 days, and the medium was then changed to fresh 1% FCS medium with or without imidaprilat, the MMP-2/9 inhibitor for 4 hours, followed by stimulation with OxLDL (100 g/mL) for 24 hours. Supernatants were subjected to SDS-PAGE in 6% (w/v) polyacrylamide gels that had been copolymerized with 0.2% gelatin. After electrophoresis, the gels were stained with Coomassie Brilliant Blue (Fluka AG). Proteolytic activity in a particular gel location yielded a clear band against the blue background of the stained gelatin.
b) MMP-9 Quenched Substrate Assays
The activity of MMP-9 in conditioned supernatants was determined using an EnzoLyte MMP-9 fluorometric assay kit (AnaSpec, Inc.). Briefly, conditioned supernatants were incubated with MMPspecific peptide substrates, based on the instructions included with the kit. Cleavage of substrates by MMPs removed the quenching effect, resulting in increased fluorescence with excitation at 360 nm and emission at 460 nm.
MMP-9 siRNA Experiment
MMP-9 siRNA was purchased from Santa Cruz. siRNA against -galactosidase (Lac Z) was used as a control. THP-1 macrophages were seeded at 7. 5 10 5 in each well of a C-6 plate and transfected with 5 L Lipofectin 2000 (Invitrogen) and the control siRNA or MMP-9 siRNA in 1 mL of Optimem (final concentration of siRNA 100 nmol/L). Thirty-six hours after transfection, the cells were co-incubated with OxLDL (100 g/mL) for 48 hours.
Statistical Analysis
Results are presented as the mean SEM. Data were analyzed using ANOVA with Tukey's post-hoc analysis. A p value 0.05 was considered significant. (A) THP-1 cells were incubated in the presence or absence of imidaprilat (100 nmol/L) for 4 hours, followed by incubation with OxLDL (100 g/mL) for 48 hours. Photos show representative oil red O staining results obtained in 3 separate experiments. (B) Bar graphs show lipid contents in THP-1 macrophages (n 4). THP-1 macrophages were incubated in the presence of the indicated concentrations of imidaprilat for the indicated periods, followed by stimulation with OxLDL (100 g/mL) for 48 hours prior to the assay. Lipid content was measured as described in Methods. Data are representative of 3 independent experiments. p 0.01 vs cont. p 0.01 vs OxLDL.
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Results
Imidaprilat Inhibits OxLDL-Induced Foam-Cell Formation by THP-1 Macrophages
We investigated the effects of imidaprilat on macrophage foam-cell formation. First, THP-1 cells were incubated in the presence of PMA at a concentration of 200 nmol/L for 3 days. After the medium was replaced with 1% FCS/RPMI medium with or without imidaprilat for 4 hours, OxLDL (100 g/mL) was added and incubated for an additional 48 hours. As shown in Fig. 1A , OxLDL induces intracellular lipid accumulation (red dye) in THP-1 macrophages. In contrast, co-treatment with imidaprilat reduced intracellular lipid accumulation. To quantitate the observed lipid accumulation, intracellular TG and TC were measured. OxLDL-mediated TG and TC accumulation in THP-1 macrophages was inhibited by imidaprilat treatment (Fig. 1B) and the inhibitory effect of imidaprilat was observed up to 100 nmol/L (p 0.01); therefore, we incubated THP-1 cells with imidaprilat at 100 nmol/L in the subsequent experiments.
Imidaprilat Decreases OxLDL-Triggered MMP-9 Activity in Culture Supernatant
Next we focused on the effects of imidaprilat on MMP-9 activity in THP-1 macrophages, since OxLDL has been reported to increase MMP-9 activity and ACEIs directly modulate that activity 13, 14) . In gelatin zymography analysis, imidaprilat reduced MMP-9 activity in the culture supernatants ( Fig. 2A) . Further, imidaprilat or the MMP-2/9 inhibitor each abolished OxLDL-induced elevation of MMP-9 activity (Fig. 2B) . The results of the quenched substrate assay revealed that OxLDL increased MMP-9 activity in the culture supernatant, which was blunted by imidaprilat (Fig. 2C) . Further, OxLDL-induced MMP-9 protein expression in THP-1 macrophages was slightly reduced by imidaprilat (Fig. 2D) .
MMP-2/9 Inhibitor Attenuates OxLDL-Induced Foam-Cell Formation
To directly link MMP-9 activity with foam-cell formation, the effects of an MMP-2/9 inhibitor were examined. As shown in Fig. 3A , treatment with the MMP-2/9 inhibitor markedly suppressed foam-cell formation induced by OxLDL. Further, TG and TC contents increased after OxLDL treatment were diminished by MMP-2/9 inhibitor treatment (Fig. 3B) . The effects of imidaprilat or the MMP-2/9 inhibitor on the expression of scavenger receptors during foam-cell formation were also examined. As shown in Fig. 4A, 4B , imidaprilat or MMP-2/9 inhibitor decreased OxLDL-triggered LOX-1 and SR-A expression in THP-1 macrophages. In contrast, the expression level of another scavenger receptor, CD36, was not changed by imidaprilat, MMP-2/9 inhibitor, or OxLDL treatment. We also examined the signaling pathways involved in the effects of imidaprilat or the MMP-2/9 inhibitor on foam-cell formation. THP-1 macrophages were pretreated for 4 hours with imidaprilat (100 nmol/L) or the MMP-2/9 inhibitor (20 mol/L) before exposure to OxLDL. As shown in Fig. 5A , OxLDL increased p38 MAPK and ERK phosphorylation, which was inhibited by imidaprilat (Fig. 5A) or the MMP-2/9 inhibitor (Fig. 5B) . Activation of JNK by OxLDL was not significantly detected under our assay conditions (data not shown).
siRNA Against MMP-9 Decreases OxLDL-Induced Foam-Cell Formation in THP-1 Macrophages
To confirm the causative role of MMP-9 in OxLDL-induced foam-cell formation, we introduced siRNA against MMP-9 into THP-1 macrophages. Transfection of THP-1 macrophages with MMP-9 siRNA successfully reduced MMP-9 expression (Fig. 6A) . Oil red O staining revealed a reduction of lipid accumulation in THP-1 macrophages transfected with MMP-9 siRNA as compared to those transfected with control siRNA following OxLDL treatment (Fig. 6B) . Moreover, the expression levels of LOX-1 and SR-A were attenuated in THP-1 macrophages transfected with MMP-9 siRNA as compared to those with control siRNA (Fig. 6C) .
Discussion
The present study demonstrated that imidaprilat, an ACEI that significantly reduces OxLDL-triggered foam-cell formation in THP-1 macrophages, is involved in inhibition of MMP-9.
OxLDL has been shown to increase the expression of ACE 23) and upregulate the angiotensin type 1 receptor in cultured human coronary artery endothelial cells 24) ; however, it is interesting that ACE expression in THP-1 macrophages was not significantly changed by OxLDL in our assay conditions (data not shown). Moreover, OxLDL treatment did not increase ACE activity in the culture supernatants (data not shown). These results suggest that the activities of imidaprilat in modulating foam-cell formation may not be related to its effect on ACE.
Collagen, as a component of the extracellular matrix, has been linked to atherosclerotic plaque formation and stability. The activity of MMP-9, a zincdependent endopeptidase, is markedly increased after myocardial infarction and rupture of abdominal aortic aneurysms 19, 25) ; therefore, MMP secretion from macrophages or smooth muscle cells could contribute to plaque rupture. OxLDL upregulates MMP-9 expression in monocyte-derived macrophages and endothelial cells 21, 26) . Further, a previous study using MMP-9 knockout mice demonstrated its importance in atherosclerosis 22) . ACE, like MMP-9, is also a zinc-dependent endopeptidase. In previous reports, ACEIs directly inhibited MMP-9 activity in tissue extracts by stabilizing hydrophobic interactions in its active domain 13, 14) . THP-1 cells were incubated in the presence or absence of imidaprilat (100 nmol/L) or MMP-2/9 inhibitor (20 mol/L) for 4 hours, followed by stimulation with OxLDL (100 g/mL) for 48 hours prior to the assay. LOX-1, SR-A and CD36 were detected with immunoblotting ( B). Data representative of 3 independent experiments.
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In line with those findings, we confirmed that an increase in MMP-9 activation in THP-1 macrophages was correlated with foam-cell formation, which was attenuated by imidaprilat treatment. Imidaprilat treatment alone diminished MMP-9 activity in culture supernatant in vitro. Furthermore, OxLDL-induced foam cell formation was diminished by treatment with the MMP-2/9 inhibitor. There is no additional effect of MMP-2/9 inhibitor on the inhibiting effect of imidaprilat. To identify the contribution of MMP-9 to the anti-inflammatory properties of imidaprilat, we conducted additional experiments using siRNA against MMP-9 and found that gene silencing of MMP-9 directly leads to successful inhibition of OxLDLinduced foam cell formation, suggesting the importance of MMP-9 in foam-cell formation. Since no MMP-2 activity was detected in THP-1 macrophage culture supernatants under our assay conditions, MMP-9 may play a primary role in macrophage foamcell formation induced by OxLDL. As previously reported, OxLDL activates MAP kinases in smooth muscle cells and macrophages 27, 28) , and that activation is critical in atherosclerosis. In the present study, we observed a reduction of ERK phosphorylation and p38 MAPK following imidaprilat treatment or the MMP-2/9 inhibitor, which suggests the importance of MAP kinases in the atheroprotective action of MMP-9 inhibition.
During the differentiation of monocytes into macrophages, scavenger receptor expression is upregulated, which is one of the key events in the process of atherosclerosis. Scavenger receptors excessively take up OxLDL, leading to their conversion to foam cells 29) . LOX-1 is a scavenger receptor that is highly expressed in atherosclerotic lesions 30, 31) . In line with these results, we found that expression levels of LOX-1 and SR-A were upregulated by OxLDL treatment, which was reduced by imidaprilat or MMP-2/9 inhibitor treat- 32) , imidaprilat or MMP-2/9 inhibitor-mediated modulation of LOX-1 may involve these pathways.
As previously reported 33) , another ACEI, captopril, also inhibits MMP-9 activity. We also confirmed that captopril decreased OxLDL-mediated TG accumulation in THP-1 macrophages (data not shown). Thus, our observation using imidaprilat may be a class effect of ACEIs. From a pathophysiological point of view, our data provide a new mechanistic explanation and a molecular basis for the potential clinical use of ACEI or MMP inhibitors to prevent OxLDL-induced foam-cell formation.
In conclusion, our results showed that an ACEI, imidaprilat, inhibited OxLDL-triggered foam-cell formation. The underlying mechanisms seem to involve the modulation of MMP-9 activity in addition to effects on ACE or reactive oxygen species (ROS) inhibition.
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